Navigation Links
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Date:3/23/2011

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the fourth and fifth years of consecutive Prolia treatment.

The data, which were presented at the annual European Congress Osteoporosis and Osteoarthritis (ECCEO11-IOF) in Valencia, Spain, showed that treatment with Prolia, the first and only approved RANK Ligand inhibitor for the treatment of postmenopausal osteoporosis, resulted in robust BMD gains after five continuous years of treatment (13.7 percent for lumbar spine BMD and 7.0 percent for total hip BMD).  

The FREEDOM Study and the 5-Year Prolia Data The pivotal FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) study established the efficacy and safety of Prolia based on three years of data from approximately 7,800 postmenopausal women. The open-label extension of FREEDOM is evaluating the long-term (up to 10 years) efficacy and safety of Prolia in 4,550 postmenopausal women. Seventy percent of eligible women from the FREEDOM study continued enrollment in the extension study; 2,343 women continued to receive Prolia treatment, and 2,207 transitioned from placebo to Prolia.

Continued treatment with Prolia resulted in consistent year-over-year gains in BMD at the lumbar spine and total hip. In years 4 and 5 respectively, women taking Prolia experienced further 1.9 percent and 1.7 percent increases in lumbar spine BMD and further 0.7 percent and 0.6 percent increases in total hip BMD (all P<0.0001 comp
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
2. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
3. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
4. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
5. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
6. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
7. MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
8. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
10. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
11. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... evolving set of regulations, Ethics & Compliance professionals ... according to a new survey issued today by ... services and education. An overwhelming majority of respondents ... far the most important component of E&C training ...
(Date:3/5/2015)... --  ndd Medical Technologies , a leader in innovative ... technology, announced that its EasyOne Pro® was used at ... Pulmonary Fibrosis Support Group. The clinic targeted patients with ... well as those suspected of having ILD or PF. ... square inches, EasyOne Pro provides accurate respiratory test results ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... and Phase 1b Combination Clinical Trials ... Anti-Leukemic Activity, SOUTH SAN FRANCISCO, Calif., June 16 ... two,clinical trials of the company,s lead drug candidate, voreloxin (formerly,SNS-595), ... when,used as a single agent in relapsed or refractory patients ...
... Patients Not Optimally Controlled with, Levodopa ... Hours Per Day, RESEARCH TRIANGLE PARK, N.C., ... announced the approval of Requip(R),XL(TM) (ropinirole extended-release tablets) ... and symptoms of idiopathic Parkinson,s disease. Requip XL ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 ... publishing company, created a unique ‘energy’ experiment to ... lives. , After quick ‘5 -7 ... more than 150+ countries reported their life improving ... respondents reported positive results. , According to research, ...
(Date:3/6/2015)... 2015 Dr. Mark Sowell recently returned from ... AZ. Offering programs for advanced education in the field of ... , As a visiting faculty member of this prestigious ... each time he visits Spear Education to participate in a ... “we are training only the top 10% and those willing ...
(Date:3/6/2015)... Alexandria, Virginia (PRWEB) March 06, 2015 ... today it has awarded five-year accreditation status to seven ... Committee mean that another 1.3 million people can now ... to protect and promote the health of their communities. ... protecting and improving the health of people and communities. ...
(Date:3/5/2015)... March 05, 2015 Shania Twain will ... than a decade. She has hinted that this will be ... seeing her perform one last time. She has had a ... beloved country sweetheart has millions of loyal fans around the world. ... native country, Canada, and on June 30th she will be at ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Risperdal ... in a Pennsylvania mass tort litigation currently underway ... a jury has begun hearing testimony in the ... atypical antipsychotic medication can cause gynecomastia, or male ... in question was filed on behalf of a ...
Breaking Medicine News(10 mins):Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... journal Addiction , researchers from Bowling Green State ... and substantially elevated risks for illegal drug use in ... incarcerated in the United States has sharply risen over ... to 2,250,000 in 2006. So too has the number ...
... 28, 2010 (Geneva, Switzerland) At the UN Millennium ... world leaders gathered to review progress on the eight ... ill-health by 2015. As the summit came to a ... $40bn to reach the goals, with particular emphasis on ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Sept. ... C-reactive protein (CRP) can vary among different racial and ... heart-disease risk and the value of cholesterol-lowering drugs, a ... of inflammation, and elevated levels have been linked -- ...
... , TUESDAY, Sept. 28 (HealthDay News) -- Think recess, and ... in the school day set aside for running and playing, ... life. What if your workplace started offering recess on the ... good idea but possibly one of the most solid tactics ...
... treatments for the disease or enable earlier diagnosis, say the ... Dentistry. Pancreatic cancer has the lowest survival rate of all ... stages, late diagnosis and its resistance to chemotherapy and radiation ... Research Fund found that nearly three quarters of pancreatic ...
... your ragweed allergies, according to a study from Queen,s University. ... develop ragweed allergy symptoms more quickly than others. But the ... swing, those symptom differences subside. The team, led ... medicine and microbiology & immunology, exposed 123 participants to ragweed, ...
Cached Medicine News:Health News:Father's incarceration associated with elevated risks of marijuana and other illegal drug use 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 3Health News:C-Reactive Protein Levels Vary By Race: Study 2Health News:C-Reactive Protein Levels Vary By Race: Study 3Health News:Adding Recess to the Workday Gains Backers 2Health News:Adding Recess to the Workday Gains Backers 3Health News:Adding Recess to the Workday Gains Backers 4Health News:Protein key to growth of pancreatic cancer 2
... Technologies, The UroMax Ultra ia designed ... high pressure and low profile., Refolding ... a remarkably strong material that is ... materials., Non-Compliant Balloons, A compliant balloon ...
... Fr Diameter with Two Large Working Channels; ... MICRO-6 Semi-Rigid Ureteroscope is the smallest ureteroscope ... and therapeutic procedures. The ACMI MICRO-6 Ureteroscope ... procedures with minimal or no dilation or ...
... is a self-dilating, semi-rigid autoclavable operating ureteroscope ... image bundle for an enhanced, clear image. ... to "0" diopters. The direction of view ... passage. The straight access operating channel is ...
... tip diameter of only 6.9Fr (2.3mm) ... range of 180 for and easy ... observation, a new optical system has ... (3.9mm) sheath dilator, 0.035" guidewire compatible, ...
Medicine Products: